Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Synonyms :
Class :
15 mg intramuscular every week for 12 weeks
The recommended dosage regimen is for 12 weeks
Provided that normal CD4+ T lymphocyte counts are present, and a minimum of 12 weeks have passed, a further 12-week course may be initiated for retreatment
This medication is used to treat moderate-severe chronic plaque psoriasis
When alefacept is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
when alefacept is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
interaction raises immunosuppressive effects and risk of infection
It may enhance and diminish the immunosuppressive effects when combined with maitake
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
It may enhance the risk of adverse reactions when combined with Ethylenimine
It may enhance the risk of adverse reactions when combined with Ethylenimine
When mometasone furoate is used together with alefacept, this leads to enhanced risk or seriousness of adverse outcomes
alefacept: it may decrease the excretion rate of abacavir CNS depressant
alefacept: it may decrease the excretion rate of abacavir CNS depressant
alefacept: it may decrease the excretion rate of abacavir CNS depressant
alefacept: it may decrease the excretion rate of abacavir CNS depressant
alefacept: it may decrease the excretion rate of abacavir CNS depressant
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
increases immunosuppressive effects of trimetrexate
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections  
increase in immunosuppression due to synergism risk of infection increases on administering both the drugs simultaneously
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
choline magnesium trisalicylate
It may enhance the risk of adverse reactions when combined with Salicylates
the risk of adverse effects may be increased
the peril or acuteness of adverse effects can be increased when alefacept is combined with stepronin